A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand.

Trial Profile

A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2015

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Peplin
  • Most Recent Events

    • 15 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 15 Jul 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Actual initiation date (Oct 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top